BFSG LLC’s Keros Therapeutics KROS Stock Holding History

BFSG LLC’s Portfolio KROS Stock Details KROS Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2024 Q1	–	Sell	-200	Closed	-$7.95K	–	684
2023 Q4	$7.95K	Buy	+200	New	+$6.27K	﹤0.01%	471

Other funds holding KROS

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Alkeon Capital Management New York $59.5B AUM 51.63% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

DGM

Darwin Global Management St. Helier, Jersey $3.77B AUM 307.72% 1-Year Est. Return

OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

Point72 Asset Management Stamford, Connecticut $78.1B AUM 55.25% 1-Year Est. Return

TCM

TCG Crossover Management Palo Alto, California $3.5B AUM 1,165.83% 1-Year Est. Return

BFSG LLC's KROS Position: Q1 2024 in Review

BFSG LLC sold out of Keros Therapeutics (KROS) in Q1 2024, closing a stake of 200 shares — an estimated $7.95K sold.

BFSG LLC first reported a position in KROS in Q4 2023 and held it in 1 quarter. The position peaked at $7.95K in Q4 2023. 147 funds tracked by Wall St. Rank hold KROS as of Q1 2024.

BFSG LLC reported no remaining Keros Therapeutics position as of Q1 2024 after selling out during the quarter.
BFSG LLC sold 200 Keros Therapeutics shares in Q1 2024, an estimated $7.95K.
BFSG LLC first reported a position in Keros Therapeutics in Q4 2023 and held it in 1 quarter.
BFSG LLC's Keros Therapeutics position peaked at $7.95K in Q4 2023.
147 funds tracked by Wall St. Rank held Keros Therapeutics as of Q1 2024.

Based on BFSG LLC's 13F filing for Q1 2024, filed 23 Apr 2024.